Last reviewed · How we verify
Mepolizumab 750
At a glance
| Generic name | Mepolizumab 750 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis (PHASE3)
- Mepolizumab in Nasal Polyposis (PHASE2)
- Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome (PHASE1, PHASE2)
- Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (PHASE2)
- Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome (PHASE1, PHASE2)
- Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (PHASE2)
- Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (PHASE2)
- Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab 750 CI brief — competitive landscape report
- Mepolizumab 750 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI